Aurobindo Pharma Q4 FY26 revenue rises 5.6% to Rs. 8,853 crore
Net profit stood at Rs. 921 crore for the quarter, while Europe revenues surged 30.2% YoY to Rs. 2,795 crore
Net profit stood at Rs. 921 crore for the quarter, while Europe revenues surged 30.2% YoY to Rs. 2,795 crore
Minister J.P. Nadda holds bilateral meeting with Helen Clark, Board Chair of the Partnership for Maternal, Newborn and Child Health in Geneva
Company’s FY26 EBITDA rses 20% to Rs. 8,475 crore; Net profit grows 15% amid strong operational performance
The drug is indicated for the maintenance treatment of patients with Chronic Obstructive Pulmonary Disease (COPD)
Initiative focuses on early diagnosis, gut health awareness and long-term gluten-free care for children with celiac disease
Growth driven by strong performance across Sugar Free, RiteBite Max Protein, Everyuth, Glucon-D and Nutralite portfolios
Growth was driven by expansion across key business segments, improving efficiencies, and sustained demand across institutional and retail channels
According to the analysis, just 23% of patients aged 18–29 were formally diagnosed with TD
FY26 revenue rises to Rs. 4,359 crore as India’s leading CDMO strengthens global footprint with EU GMP certifications, UK MHRA approval and Europe supplies
Subscribe To Our Newsletter & Stay Updated